Search

Displaying results 7941 - 7950 of 10000 in total
  1. Drug

    (S)-AMPA

    go.drugbank.com/drugs/DB02057
    Experimental

    AMPA is a specific agonist for the AMPA receptor.

  2. Drug

    Proscillaridin

    go.drugbank.com/drugs/DB13307
    Experimental

    Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations [A27193 … Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima).

  3. Drug

    Ruserontinib

    go.drugbank.com/drugs/DB21555
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor.

  4. Drug

    Vociprotafib

    go.drugbank.com/drugs/DB21559
    Investigational

    The usage of the INN stem '-protafib' in the name indicates that Vociprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor.

  5. Drug

    Enbezotinib

    go.drugbank.com/drugs/DB21565
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Enbezotinib is a tyrosine kinase inhibitor.

  6. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. … It is a component of both intra- and extracellular fluids and is excreted in the urine and feces.

  7. Drug

    KB002

    go.drugbank.com/drugs/DB05194
    Experimental

    It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.

  8. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  9. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.

  10. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]